Janssen Plans New U.S. Filing For Xarelto, Based On Positive EINSTEIN-PE Results
This article was originally published in The Pink Sheet Daily
In study of almost 5,000 patients, Janssen/Bayer’s novel anticoagulant proves non-inferior on efficacy compared to old standard of care, with significantly less major bleeding. A mostly one-drug, oral approach could help differentiate the drug from rivals in venous thromboembolism prevention.
You may also be interested in...
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.